Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

A multicenter prospective study to assess the efficacy and safety of ZOMETA® in treatment of high-level NTX non small cell lung cancer with bone metastasis.

Inclusion Criteria:

• Age > 18
• Histologically confirmed non-small cell cancer
• One bone metastasis at least confirmed by image(X ray, CT or others)
• NTX > 50nM BCE/mM creatinine
• Life expectancy > 6 M
• ECOG <= 2
• Signed ICF

Exclusion Criteria:

• Women who are pregnant or in lactation
• Patients with hyperostosis with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled
• Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy
• Severe co-morbidity of any type that may interfere with assessment of the patient for the study -